What innovative pricing strategy did Broad Institute and MIT implement for their CRISPR-Cas9 patents to balance commercial interests with scientific advancement?

The CRISPR gene-editing technology represents one of the most significant scientific breakthroughs of the 21st century. Beyond its revolutionary scientific applications, CRISPR has introduced fascinating pricing challenges and strategies in the biotech industry. This poll explores how this groundbreaking technology navigated the complex intersection of scientific innovation, accessibility, and commercial viability.

This is a live public trivia poll on AIPolls.Net. Vote and see real-time results.

Tiered licensing: lower fees for academic research, higher fees for commercial applications
Subscription model: monthly access fees based on number of experiments conducted
Outcome-based pricing: royalties only collected on successful gene edits
Open-source pricing: completely free access with mandatory data sharing